GI Innovation Inc
KOSDAQ:358570
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Raydan Food Company SJSC
SAU:6012
|
SA |
GI Innovation Inc
Total Current Liabilities
GI Innovation Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
GI Innovation Inc
KOSDAQ:358570
|
Total Current Liabilities
₩4.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Total Current Liabilities
₩4.5T
|
CAGR 3-Years
51%
|
CAGR 5-Years
33%
|
CAGR 10-Years
21%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Total Current Liabilities
₩21.3B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Total Current Liabilities
₩6.8B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Total Current Liabilities
₩239.7B
|
CAGR 3-Years
36%
|
CAGR 5-Years
62%
|
CAGR 10-Years
89%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Total Current Liabilities
₩123.5B
|
CAGR 3-Years
20%
|
CAGR 5-Years
73%
|
CAGR 10-Years
N/A
|
|
GI Innovation Inc
Glance View
GI Innovation, Inc. engages in the development of biopharmaceutical products. The company is headquartered in Seoul, Seoul and currently employs 88 full-time employees. The company went IPO on 2023-03-30. The firm is engaged in the business of generating revenue through license fees by technology transfer of new drug candidates in pre-clinical and early clinical stages. The core new drug pipeline includes products such as GI-101 immuno-oncology and GI-301 allergy treatment.
See Also
What is GI Innovation Inc's Total Current Liabilities?
Total Current Liabilities
4.7B
KRW
Based on the financial report for Dec 31, 2024, GI Innovation Inc's Total Current Liabilities amounts to 4.7B KRW.
What is GI Innovation Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 3Y
-3%
Over the last year, the Total Current Liabilities growth was -19%. The average annual Total Current Liabilities growth rates for GI Innovation Inc have been -3% over the past three years .
